Economic assessment of delaying insulin treatment through the use of newer anti-diabetic agents, dapagliflozin (Forxiga®) and exenatide (Bydureon®), both as add-on to metformin; a cost-effectiveness analysis from a Uk NHS perspective

Authors: M Charokopou, H Vioix, B G Verheggen, D Maddocks, T Bratt, D Franks

Published: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2014